



## CORE ASSAY LIST 2008

### METABOLIC

REF #	PROJECT TYPE	ASSAY PRINCIPLE	 TURNAROUND TIME	MINIMUM COMPOUND REQUIRED	STANDARD FORMAT
PZR1	CustomMapping™	<p><b>Test model:</b> Determination of gene expression in human tissues (tissues selected by client, diseased and non-diseased). Compare gene expression between diseased and non-diseased tissues for target and biomarker validation.</p> <p><b>Assay format:</b> qRT-PCR.</p> <p><b>Data format:</b> Word™ report with data available in an Excel™ file.</p>	6 weeks (assumes no tissue sourcing required)	N/A	Profiling of 1 to 20 genes in up to 182 tissues and includes a final report. COST PER GENE REDUCES SIGNIFICANTLY THE MORE THAT ARE PROFILED.
PZR2	<i>In situ</i> hybridization	<p><b>Test model:</b> Determination of gene expression in frozen sections of human tissues (selected by client, diseased and non-diseased). Identify expression patterns of target mRNA at the cellular level to understand potential function of the gene of interest and its possible role in disease.</p> <p><b>Assay format:</b> <i>In situ</i> hybridization.</p> <p><b>Data format:</b> Standard ISH report to include detailed description of distribution of mRNA expression on target mRNAs in frozen sections of human tissues.</p>	Stage 1 and Stage 2 in approx. 4-5 weeks	cDNA clones or accession number of mRNA sequence and any information on suitable positive control human tissue	1 target, 1 tissue, 3 donors. Using validated riboprobe pairs.
PZR3	Immunohistochemistry	<p><b>Test model:</b> Determination of protein expression in human tissues (selected by client, diseased and non-diseased). identify the pattern of expression of a target protein at the cellular level to understand potential function of that target and its possible role in disease.</p> <p><b>Assay format:</b> Immunohistochemistry.</p> <p><b>Data format:</b> Standard IHC report to include detailed description of patterns and levels of target protein expression in either FFPE or frozen sections of human met tissues.</p>	Stage 1 and Stage 2 in approx. 4-5 weeks	Proprietary antibodies or nomination of commercially available antibodies	1 target, 1 tissue, 6 donors. Full scale Stage 1 optimization.

# METABOLIC

REF #	PROJECT TYPE	ASSAY PRINCIPLE	 TURNAROUND TIME	MINIMUM COMPOUND REQUIRED	STANDARD FORMAT
PZR4	FFPE Tissue Arrays	<p><b>Test model:</b> Localization of target proteins in custom made metabolic disease TMAs. Screen and analyze many tissues and disease indications simultaneously.</p> <p><b>Assay format:</b> Tissue microarray.</p> <p><b>Data format:</b> Word™ report with clinical and experimental datasets and JPEG images to illustrate main findings.</p>		N/A	<p>1 target in a 250 core FFPR tissue microarray</p> <p>Full scale Stage I optimization with positive control tissues</p>
PZME - 05	Functional binding	<p><b>Test model:</b> Brain: striatum. [35S]-GTPγS binding in response to standard and test compounds. This test produces support for preclinical development by assessing the functional efficacy of a compound via modulation of native receptors.</p> <p><b>Assay format:</b> Functional binding assay.</p> <p><b>Data format:</b> Word™ report with data available in an Excel™ file.</p>	3 weeks per donor	5mg	<p><b>Standard conditions:</b> up to 3 test compounds (plus 1 standard compound) per experiment, 9 point concentration effect curves in triplicate</p> <p>Membranes from 1 brain region</p> <p>Maximum 1.5 x 96-well plates per experiment</p>
PZME - 06	Fatty Acid Oxidation	<p><b>Test model:</b> Hepatocytes. Determination of fatty acid oxidation in response to standard and test compounds. Useful for the lead optimization for diabetes compounds or to investigate potential compound side-effects.</p> <p><b>Assay format:</b> Incubations in 12-well plates. [14C]CO2 capture. Fatty acid oxidation.</p> <p><b>Data format:</b> Word™ report with data available in an Excel™ file.</p>	3 weeks per donor	5mg	Up to 12 compounds at 1 concentration in triplicate
PZME - 07	GSIS Assay	<p><b>Test Model:</b> Measurement of induction of glucose stimulated insulin secretion in human isolated pancreatic islets. This approach is useful for assessing the effectiveness of compounds under development for the treatment of type 2 diabetes.</p> <p><b>Assay Format:</b> Incubation within a 96 well plate format and analysis by ELISA.</p> <p><b>Data Format:</b> Word™ report with data available in an Excel™ file.</p>	6 weeks per donor	5mg	<p>4 plate assay</p> <p>Testing of a maximum of 18 compounds (single concentration) at 2 glucose concentrations</p>

For ordering and updated information go to [www.asterand.com](http://www.asterand.com) or call us at **US 313 263 0960/Europe +44 (0) 1763 211600**